3-ethyl-hex-4t-en-3-ol | 101567-71-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-ethyl-hex-4t-en-3-ol
• 英文别名: 3-ethyl-hex-4-en-3-ol；3-Aethyl-hex-4t-en-3-ol；Diaethylpropenylcarbinol；3-Aethyl-hex-4-en-3-ol；(E)-3-ethylhex-4-en-3-ol
• CAS: 101567-71-9
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: NLSZGRWKFRRFDA-QPJJXVBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-ethyl-hex-4t-en-3-ol 生成 allophanic acid-(1,1-diethyl-but-2t-enyl ester)
  参考文献：
  名称：

  Acyloxysilanes and Their Reaction with Grignard Reagents¹

  摘要：

  DOI：

  10.1021/jo01096a036
• 作为产物：
  描述：

  反式-巴豆腈(含有约20的顺式同分异构体) 、 乙基溴化镁 生成 3-ethyl-hex-4t-en-3-ol
  参考文献：
  名称：

  Bruylants; Mathus, Bulletin de la Classe des Sciences, Academie Royale de Belgique, 1925, vol. <5> 11, p. 637,638

  摘要：

  DOI：

文献信息

• Phenyl-thiophene type vitamin D receptor modulators
  申请人：Eli Lilly & Company

  公开号：EP2184281A1

  公开（公告）日：2010-05-12

  The present invention relates to novel, non-secosteroidal, phenyl-thiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

  本发明涉及具有维生素 D 受体（VDR）调节活性的新型非甾体苯基噻吩化合物，其高钙血症性低于 1α，25 二羟基维生素 D3。这些化合物可用于治疗骨病和牛皮癣。
• Breckpot, Bulletin des Societes Chimiques Belges, 1923, vol. 32, p. 421,426
  作者：Breckpot

  DOI：——

  日期：——
• VITAMIN D RECEPTOR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1687292B1

  公开（公告）日：2007-08-22
• MICROBIAL SYNTHESIS OF ISOPRENOID PRECURSORS, ISOPRENOIDS AND DERIVATIVES INCLUDING PRENYLATED AROMATICS COMPOUNDS
  申请人：William Marsh Rice University

  公开号：EP3430151A1

  公开（公告）日：2019-01-23
• [EN] MICROBIAL SYNTHESIS OF ISOPRENOID PRECURSORS, ISOPRENOIDS AND DERIVATIVES INCLUDING PRENYLATED AROMATICS COMPOUNDS<br/>[FR] SYNTHÈSE MICROBIENNE DE PRÉCURSEURS D'ISOPRÉNOÏDES, D'ISOPRÉNOÏDES ET DE DÉRIVÉS COMPRENANT DES COMPOSÉS AROMATIQUES PRÉNYLÉS
  申请人：UNIV RICE WILLIAM M

  公开号：WO2017161041A1

  公开（公告）日：2017-09-21

  This disclosure generally relates to the use of enzyme combinations or recombinant microbes comprising same to make isoprenoid precursors, isoprenoids and derivatives thereof including prenylated aromatic compounds. Novel metabolic pathways exploiting Claisen, aldol, and acyioin condensations are used instead of the natural mevalonate (MVA) pathway or 1-deoxy-d-xylulose 5-phosphate (DXP) pathways for generating isoprenoid precursors such as isopentenyl pyrophosphate (IPP), dimethylallyl pyrophosphate (DMAPP), and geranyl pyrophosphate (GPP). These pathways have the potential for better carbon and or energy efficiency than native pathways. Both decarboxylative and non-carboxylative condensations are utilized, enabling product synthesis from a number of different starting compounds. These condensation reactions serve as a platform for the synthesis of isoprenoid precursors when utilized in combination with a variety of metabolic pathways and enzymes for carbon rearrangement and the addition/removal of functional groups. Isoprenoid alcohols are key intermediary products for the production of isoprenoid precursors in these novel synthetic metabolic pathways.